Clinical status of metastatic melanoma patients and enumeration of A2/Melan A tetramer binding lymphocytes in TIL(N)
| Patient Codea | Age (yr) | Tumor Stage (AJCC)b | Samplea | %CD8+ in Lymphocyte Gatec | %CD8+ A2/Melan-A Tetramer+ |
|---|---|---|---|---|---|
| LAU 156 | 50 | T3N0M1 | Paravertebral metastasis | 97 | 9.7 |
| LAU 156 | 51 | T3N0M1 | Paravertebral metastasis | 85.4 | 14.7 |
| LAU 212 | 71 | pTXN2cM0 | Subcutaneous metastasis | 92 | 3.9 |
| LAU 337 | 25 | pT3aN2M1 | Soft tissue metastasis | 34.2 | 0.3 |
| LAU 321 | 65 | pT2N2cM0 | Subcutaneous metastasis | 65.5 | 0.2 |
| LAU 343 | 78 | pT3aN2cM0 | Subcutaneous metastasis | 63.6 | 15.5 |
| LAU 253 | 61 | pT3aN2M0 | Tumor-infiltrated lymph node | 62.3 | 21.8 |
| LAU 50 | 65 | pT4aN2cM0 | Tumor-infiltrated lymph node | 47.5 | 14.5 |
| LAU 233 | 75 | pT4N2cM0 | Tumor-infiltrated lymph node | 87.4 | 24.4 |
| LAU 203 | 66 | pTxN2cM0 | Tumor-infiltrated lymph node | 98 | 4.9 |
| LAU 314 | 42 | pT2N0M1 | Tumor-infiltrated lymph node | 67.7 | <0.01 |
| LAU 198 | 71 | pT3aN1M0 | Tumor-infiltrated lymph node | 52.8 | <0.01 |
a All samples included in this series were collected by surgical dissection, finely minced with needles and cultured for 2–3 wk in complete medium supplemented with hrIL-2 and hrIL-7.
b AJCC, American Joint Committee on Cancer.
c Aliquots of TIL(N) were analyzed by two-color flow cytometry after staining with anti-CD8 and A2/Melan-A tetramers. CD8bright cells were gated, and the percentage of CD8+ A2/Melan-A tetramer+ cells was calculated with CellQuest software.